I work in the Policy and Campaigns team at Breast Cancer Now.
As you may be aware abemaciclib (Verzenio) and ribociclib (Kisqali) were both approved in combination with fulvestrant by the National Institute for Health and Care Excellence (NICE) on the NHS via the Cancer Drugs Fund.
The Cancer Drugs Fund is a route which provides access to promising new treatments on the NHS while further data is collected about a drug to address any areas of clinical uncertainty that were identified during the assessment process. Following this data collection period, NICE will shortly be re-reviewing the use of these two treatments on the NHS.
We're currently gathering evidence and insights to help inform our response and highlight the importance of these treatment options. As part of this we would like to hear from anybody who has received either abemaciclib or ribociclib in combination with fulvestrant to hear your experiences of these treatments and inform our work.
If you are able to help, please complete this short form by 21st September https://breastcancernow.org/about-us/tell-us-your-story
With best wishes,